Physician profile
Robert D Collins
NPI 1851474092
$5,250.72
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $871 · 2021: $918 · 2022: $1,008 · 2023: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,199.73 | 2019-2023 | Cimzia |
| Abbvie INC. | $1,015.30 | 2019-2023 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $795.09 | 2019-2023 | |
| Amgen INC. | $418.92 | 2019-2023 | Enbrel, Otezla, Evenity |
| Lilly USA, LLC | $318.77 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $280.42 | 2019-2023 | Benlysta |
| Pfizer INC. | $270.43 | 2019-2023 | |
| Horizon Therapeutics Plc | $269.93 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $122.27 | 2022-2023 | Saphnelo |
| Regeneron Healthcare Solutions, INC. | $93.61 | 2019 | |
| Radius Health, INC. | $89.95 | 2019-2023 | Tymlos |
| Genentech USA, INC. | $78.05 | 2019-2023 | Actemra |
| Sandoz INC. | $65.73 | 2023 | Hyrimoz |
| Genzyme Corporation | $53.42 | 2021-2023 | |
| Janssen Biotech, INC. | $44.12 | 2022-2023 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $43.48 | 2023 | Iovera, Zilretta |
| E.R. Squibb & Sons, L.L.C. | $34.57 | 2020-2023 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.13 | 2023 | Cyltezo |
| Aurinia Pharma U.S., INC. | $27.80 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.